Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180255 · ClinicalTrials.gov registry record · Phase 2
Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery
A Phase 2 study, sponsored by Eyegate Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT03180255: Completed Phase 2 study, sponsored by Eyegate Pharmaceuticals.
NCT03180255 is a Phase 2 study that has completed, run by Eyegate Pharmaceuticals. The registered enrollment target is 101 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03180255, a Phase 2 study, has completed, sponsored by Eyegate Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
Phase 2b trial evaluating the safety and efficacy of EGP-437, versus placebo using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with implantation of a monofocal posterior chamber intraocular lens (IOL).
Primary Outcome
The proportion of subjects with an AC cell count of zero on Day 7
Interventions
- OTHER Placebo
- COMBINATION_PRODUCT Dexamethasone phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2017-11-27 |
| Phase | Phase 2 |
What the finished NCT03180255 record still lists
NCT03180255 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03180255 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03180255 about?
NCT03180255 is a clinical study titled "Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery". Phase 2b trial evaluating the safety and efficacy of EGP-437, versus placebo using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with implantation of a monofocal posterior chamber intraocular lens (IOL).
What is the current status of trial NCT03180255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2017-07-26. Estimated completion is 2017-11-27.
What interventions are being tested in trial NCT03180255?
The interventions under investigation include: Placebo (OTHER), Dexamethasone phosphate (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03180255?
This trial is sponsored by Eyegate Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03180255's enrollment target sits among peer trials
101 672nd of 2000 higher than 1,329 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI